(Reuters) – Amgen Inc stated on Friday that the U.S. Food and Drug Administration permitted its drug, Xgeva, to stop fractures in sufferers with a number of myeloma.
Xgeva has already been permitted to deal with a situation during which the calcium stage in blood is above regular and big cell tumor of the bone.
Amgen reacquired gross sales rights to Xgeva together with two different medicine from British drugmaker GlaxoSmithKline in 2015.(reut.rs/2F43mf5)
The deal gave the drugmaker rights to promote in 48 nations, together with Australia in addition to markets in Asia, South America and Europe.
Xgeva is one of Amgen’s key development drivers and had raked in $1.53 billion in gross sales in 2016.
Reporting by Akankshita Mukhopadhyay in Bengaluru